260 related articles for article (PubMed ID: 17099362)
1. Childhood tumors of the nervous system as disorders of normal development.
Grimmer MR; Weiss WA
Curr Opin Pediatr; 2006 Dec; 18(6):634-8. PubMed ID: 17099362
[TBL] [Abstract][Full Text] [Related]
2. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
[TBL] [Abstract][Full Text] [Related]
3. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
[TBL] [Abstract][Full Text] [Related]
4. The MYCN oncogene and differentiation in neuroblastoma.
Westermark UK; Wilhelm M; Frenzel A; Henriksson MA
Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159
[TBL] [Abstract][Full Text] [Related]
5. BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma.
Shackleford GM; Shi XH; Swanson KS; Mahdi MY; Gonzalez-Gomez I; Asgharzadeh S; D'Apuzzo M; Erdreich-Epstein A; Moats RA
PLoS One; 2016; 11(6):e0156907. PubMed ID: 27310018
[TBL] [Abstract][Full Text] [Related]
6. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.
Swartling FJ; Savov V; Persson AI; Chen J; Hackett CS; Northcott PA; Grimmer MR; Lau J; Chesler L; Perry A; Phillips JJ; Taylor MD; Weiss WA
Cancer Cell; 2012 May; 21(5):601-613. PubMed ID: 22624711
[TBL] [Abstract][Full Text] [Related]
7. Pleiotropic role for MYCN in medulloblastoma.
Swartling FJ; Grimmer MR; Hackett CS; Northcott PA; Fan QW; Goldenberg DD; Lau J; Masic S; Nguyen K; Yakovenko S; Zhe XN; Gilmer HC; Collins R; Nagaoka M; Phillips JJ; Jenkins RB; Tihan T; Vandenberg SR; James CD; Tanaka K; Taylor MD; Weiss WA; Chesler L
Genes Dev; 2010 May; 24(10):1059-72. PubMed ID: 20478998
[TBL] [Abstract][Full Text] [Related]
8. Induction of medulloblastomas in mice by sonic hedgehog, independent of Gli1.
Weiner HL; Bakst R; Hurlbert MS; Ruggiero J; Ahn E; Lee WS; Stephen D; Zagzag D; Joyner AL; Turnbull DH
Cancer Res; 2002 Nov; 62(22):6385-9. PubMed ID: 12438220
[TBL] [Abstract][Full Text] [Related]
9. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY
Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452
[TBL] [Abstract][Full Text] [Related]
10. Episomal amplification of MYCN in a case of medulloblastoma.
Surace C; Pedeutour F; Trombetta D; Burel-Vandenbos F; Rocchi M; Storlazzi CT
Virchows Arch; 2008 May; 452(5):491-7. PubMed ID: 18286303
[TBL] [Abstract][Full Text] [Related]
11. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA
Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of genomic aberrations during clinical progression of medulloblastoma.
Korshunov A; Benner A; Remke M; Lichter P; von Deimling A; Pfister S
Acta Neuropathol; 2008 Oct; 116(4):383-90. PubMed ID: 18704466
[TBL] [Abstract][Full Text] [Related]
15. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
[TBL] [Abstract][Full Text] [Related]
16. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
[TBL] [Abstract][Full Text] [Related]
18. Medulloblastoma: developmental mechanisms out of control.
Marino S
Trends Mol Med; 2005 Jan; 11(1):17-22. PubMed ID: 15649818
[TBL] [Abstract][Full Text] [Related]
19. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
Weber A; Imisch P; Bergmann E; Christiansen H
J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
[TBL] [Abstract][Full Text] [Related]
20. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
Slack A; Lozano G; Shohet JM
Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
